Article
Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy.
AIDS (London, England) - 1 Jun 2011
Murphy Alison A, Herrmann Eva, Osinusi Anu O, Wu Lynn, Sachau William, Lempicki Richard A, Yang Jun, Chung Tje L, Chung Tei L, Wood Brad J, Haagmans Bart L, Kottilil Shyam, Polis Michael A
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV)/HIV co-infected patients have more rapid progression of liver fibrosis and only modest cure rates (sustained virologic responses, SVRs) when compared to HCV monoinfected patients. METHOD: We compared the virologic responses of either twice-weekly peginterferon-α-2a 180 μg/week (for 4 weeks, followed by weekly dosing) or weekly peginterferon-α-2a 180 μg/week, and weight-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.